Literature DB >> 11297456

Progress toward the development of a safe and effective agent for treating reentrant cardiac arrhythmias: synthesis and evaluation of ibutilide analogues with enhanced metabolic stability and diminished proarrhythmic potential.

J B Hester1, J K Gibson, L V Buchanan, M G Cimini, M A Clark, D E Emmert, M A Glavanovich, R J Imbordino, R J LeMay, M W McMillan, S C Perricone, D M Squires, R R Walters.   

Abstract

A series of ibutilide analogues with fluorine substituents on the heptyl side chain was prepared and evaluated for class III antiarrhythmic activity, metabolic stability, and proarrhythmic potential. It was found that fluorine substituents stabilized the side chain to metabolic oxidation. Many of the compounds also retained the ability to increase the refractoriness of cardiac tissue at both slow and fast pacing rates. The potential for producing polymorphic ventricular tachycardia in the rabbit model was dependent on the chirality of the benzylic carbon. The S-enantiomers generally had less proarrhythmic activity than the corresponding racemates. One compound from this series (45E, trecetilide fumarate) had excellent antiarrhythmic activity and metabolic stability and was devoid of proarrhythmic activity in the rabbit model. It was chosen for further development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11297456     DOI: 10.1021/jm0004289

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Synthesis of (E)- and (Z)-alpha,beta-Difluorourocanic Acid.

Authors:  Jan Hajduch; Bohumil Dolenský; Shinichi Yoshida; Junfa Fan; Kenneth L Kirk
Journal:  J Fluor Chem       Date:  2008-02       Impact factor: 2.050

2.  Murine Efficacy and Pharmacokinetic Evaluation of the Flaviviral NS5 Capping Enzyme 2-Thioxothiazolidin-4-One Inhibitor BG-323.

Authors:  Kristen M Bullard; Rebekah C Gullberg; Elnaz Soltani; J Jordan Steel; Brian J Geiss; Susan M Keenan
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.